johnson & johnson - Search News

Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Business Insider · 16h

Johnson & Johnson Q4 Profit Decreases, But Beats Estimates

Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The

AOL · 13h

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh

Zacks.com on MSN · 16h

Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.

FDA approves Johnson & Johnson’s nasal spray for depression

Fortune on MSN · 3h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

U.S. News & World Report · 11h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Popular Science · 12h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Ben Johnson takes a jab at Matt LaFleur

USA TODAY Touchdown Wire o… · 4h

Ben Johnson praises Lions players, organization in first press conference with Bears

Former Detroit Lions offensive coordinator Ben Johnson officially joined the division rival Chicago Bears on Tuesday, and the team introduced him as their new head coach in a news conference on Wed

ESPN · 6h

Ben Johnson takes a jab at Matt LaFleur during introductory news conference

Bears head coach Ben Johnson makes a joke about beating Packers coach Matt LaFleur twice a season.

Yahoo! Sports · 9h

'I kinda enjoyed beating Matt LaFleur': Takeaways from Ben Johnson's Chicago Bears press conference

Here are our takeaways from Ben Johnson's introductory press conference as the Chicago Bears' next head coach.

Aaron Glenn, Ben Johnson

The Washington Post · 1d

With Ben Johnson on the move to Chicago, 5 head coaching vacancies remain

Ben Johnson made a quick decision. Aaron Glenn could be next. With Johnson heading to Chicago and Mike Vrabel already in New England, five head coaching vacancies remain. The Jets, Saints, Jaguars, Raiders and Cowboys are still in the hunt.

Fox Sports · 6h

With Aaron Glenn going to the Jets, 4 head coaching vacancies remain

Aaron Glenn is joining Ben Johnson on the move to a head coaching position. Glenn agreed to take over the New York Jets on Wednesday, according to a person with knowledge of the decision. The person spoke to The Associated Press on condition of anonymity because the team had not yet announced the hiring.

CBSSports.com · 9h

Lions lose Aaron Glenn, Ben Johnson to head coaching jobs: Identifying internal replacements for coordinators

Now, the Lions are also starting over at both the offensive coordinator and defensive coordinator positions on their coaching staff, with OC Ben Johnson being hired to be the next head coach of the Chicago Bears and DC Aaron Glenn being hired to be the next head coach of the New York Jets.

13h

Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

MassDevice16h

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

12hon MSN

Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

15h

Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond

Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...

23h

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...

TipRanks on MSN3d

Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards

Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Johnson & Johnson Q4 Profit Decreases

FDA approves Johnson & Johnson’s nasal spray for depression

Ben Johnson takes a jab at Matt LaFleur

Aaron Glenn, Ben Johnson

Related topics